Product description
Alogliptin benzoate is a serine protease dipeptide peptidase IV (DPP-IV) inhibitor developed by Takeda Corporation in Japan. This product can maintain the levels of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulin-like growth peptide (GIP) in the body and promote the secretion of insulin to play a hypoglycemic role. Results of a randomized, placebo-controlled clinical trial showed that alogliptin monotherapy significantly improved glycemic control in patients with type 2 diabetes compared with placebo, did not increase the incidence of hypoglycemia and was well tolerated. The drug, together with sitagliptin and Vigagliptin components, is a specific and effective oral DPP-IV inhibitor, which provides a new treatment option for type 2 diabetes patients and has broad application prospects.
About us
Hebei Ganmiao New Materials Technology Co., Ltd. is a
A new type of chemical enterprise that integrates research and development, production, and sales.
Our company mainly produces pharmaceutical raw materials and intermediates.
In recent years, we have made significant breakthroughs in the fields of feed additives, plant extraction, and industrial chemicals.
With the philosophy of "honest operation, quality control, and customer first", our company enjoys a good reputation both domestically and internationally.
Our production process strictly complies with ISO 9001 and ISO 2000 standards. Our laboratory and workshop also strictly adhere to GMP standards. Our products are sold to Europe, North and South America, Northeast China, Asia Pacific region, and Africa, and we have established long-term stable business relationships. We have large liquid chemical terminals and professional chemical warehouses.
We will always adhere to expanding our business scope and providing the world with the highest quality products and services
China
